JPMorgan Chase & Co. Boosts Stock Position in Privia Health Group, Inc. (NASDAQ:PRVA)

JPMorgan Chase & Co. raised its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 8.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 188,384 shares of the company's stock after purchasing an additional 14,641 shares during the quarter. JPMorgan Chase & Co. owned 0.16% of Privia Health Group worth $3,430,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of PRVA. Canada Pension Plan Investment Board acquired a new position in Privia Health Group in the 2nd quarter worth approximately $26,000. GAMMA Investing LLC increased its stake in shares of Privia Health Group by 98.7% in the third quarter. GAMMA Investing LLC now owns 1,701 shares of the company's stock worth $31,000 after acquiring an additional 845 shares during the period. Quarry LP raised its holdings in shares of Privia Health Group by 344.6% during the third quarter. Quarry LP now owns 3,268 shares of the company's stock worth $60,000 after purchasing an additional 2,533 shares during the last quarter. KBC Group NV lifted its position in Privia Health Group by 34.6% during the third quarter. KBC Group NV now owns 3,385 shares of the company's stock valued at $62,000 after purchasing an additional 871 shares during the period. Finally, Neo Ivy Capital Management purchased a new stake in Privia Health Group in the third quarter valued at $66,000. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on PRVA shares. KeyCorp started coverage on shares of Privia Health Group in a research note on Friday, October 11th. They issued an "overweight" rating and a $23.00 target price for the company. Stephens reaffirmed an "overweight" rating and issued a $26.00 price target on shares of Privia Health Group in a report on Thursday, January 2nd. Macquarie initiated coverage on Privia Health Group in a research report on Monday, December 16th. They issued an "outperform" rating and a $25.00 price objective for the company. JPMorgan Chase & Co. boosted their price target on shares of Privia Health Group from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Friday, November 29th. Finally, Needham & Company LLC assumed coverage on shares of Privia Health Group in a research report on Friday, January 10th. They issued a "buy" rating and a $25.00 target price on the stock. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $24.88.

Privia Health Group Stock Performance

Shares of Privia Health Group stock traded up $0.39 during trading hours on Friday, hitting $22.24. The company's stock had a trading volume of 446,321 shares, compared to its average volume of 536,966. The firm has a fifty day moving average of $21.01 and a 200-day moving average of $19.60. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of 222.42, a P/E/G ratio of 2.77 and a beta of 0.85. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $23.24.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.